ArticleACS pharmacology & translational science2020
Characterization of the Core Ribosomal Binding Region for the Oxazolidone Family of Antibiotics Using Cryo-EM.
Article in ACS pharmacology & translational science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Designing the Next Generation of Antibiotics: Structure, SAR, and Strategy in Medicinal Chemistry (2000-2025).Medicinal research reviews · 2026Review
- Metabolism-Based Biomarkers for Rapid Phenotypic Antibiotic Susceptibility Testing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- A cost-effective 200 kV cryo-EM core facility for high resolution single particle analysis.Methods in microscopy · 2026Article
- Article
- Discovery and development of a new oxazolidinone with reduced toxicity for the treatment of tuberculosis.Nature medicine · 2026Article
- Safety and Effectiveness of Contezolid versus Linezolid in Drug-Resistant Tuberculosis: A 12-Month Retrospective Study from China.Infection and drug resistance · 2026Article
- Efficacy and Safety of Contezolid as Salvage Treatment for Gram-Positive Bacterial Infections: A Retrospective Multicenter Study.Infection and drug resistance · 2026Article
- Synthesis and antibacterial activity of novel benzodioxin-containing oxazolidinones against M. abscessus.Bioorganic & medicinal chemistry letters · 2025Article
- Concentration of contezolid in cerebrospinal fluid and serum in a patient with renal allograft tuberculosis and tuberculous meningoencephalitis.BMC infectious diseases · 2025Article
- Redesigning oxazolidinones as carbonic anhydrase inhibitors against vancomycin-resistant enterococci.European journal of medicinal chemistry · 2025Article
- Advances in contezolid: novel oxazolidinone antibacterial in Gram-positive treatment.Infection · 2024Review
- Ribosome-targeting antibiotics and resistanceRSC medicinal chemistry · 2023Review
- Comparative Assessment of Docking Programs for Docking and Virtual Screening of Ribosomal Oxazolidinone Antibacterial Agents.Antibiotics (Basel, Switzerland) · 2023Article
- A Comprehensive Overview of the Antibiotics Approved in the Last Two Decades: Retrospects and Prospects.Molecules (Basel, Switzerland) · 2023Review
- Contezolid, a novel oxazolidinone antibiotic, may improve drug-related thrombocytopenia in clinical antibacterial treatment.Frontiers in pharmacology · 2023Article
- A Structurally CharacterizedMicrobiology spectrum · 2022Article
- Strategies to Improve the Potency of Oxazolidinones towards Bacterial Biofilms.Chemistry, an Asian journal · 2022Review
- Structural basis for context-specific inhibition of translation by oxazolidinone antibiotics.Nature structural & molecular biology · 2022Article
- Compassionate Use of Contezolid for the Treatment of Tuberculous Pleurisy in a Patient with a Leadless Pacemaker.Infection and drug resistance · 2022Article
- Mechanistic Insights into the Capsule-Targeting Depolymerase from a Klebsiella pneumoniae Bacteriophage.Microbiology spectrum · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Linezolid and tedizolid are oxazolidinones with established clinical utility for the treatment of Gram-positive pathogens. Over time it has become apparent that even modest structural changes to the core phenyl oxazolidinone leads to drastic changes in biological activity. Consequently, the structure-activity relationship around the core oxazolidinone is constantly evolving, often reflected with new structural motifs present in nascent oxazolidinones. Herein we describe the use of cryo-electron microscopy to examine the differences in binding of several functionally different oxazolidinones in the hopes of enhanced understanding of their SAR. Tedizolid, radezolid, T145, and contezolid have been examined within the peptidyl transferase center (PTC) of the 50S ribosomal subunit from methicillin resistant
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.